Physician profile
Yan Wolfson
NPI 1760404529
$5,649.42
in general payments reported to CMS, 2019-2025
36 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $654 · 2021: $808 · 2022: $513 · 2023: $584 · 2024: $925 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,609 · Education: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,608.76 |
| Education | $382.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,123.86 | 2019-2025 | Xtandi, Myrbetriq, Padcev |
| Endo Pharmaceuticals INC. | $722.47 | 2019-2023 | Xiaflex, Aveed |
| Teleflex LLC | $713.81 | 2023-2025 | Urolift, Barrigel, Solesta |
| Pfizer INC. | $579.04 | 2019-2025 | |
| Boston Scientific Corporation | $341.98 | 2022-2025 | Spaceoar Vue System - 10ml, Rezum Generator, Advance Xp |
| Janssen Biotech, INC. | $329.00 | 2019-2021 | |
| Calyxo, INC. | $274.05 | 2025 | Cvac Aspiration System |
| Bayer Healthcare Pharmaceuticals INC. | $208.49 | 2021-2025 | |
| Procept Biorobotics Corporation | $197.73 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Axonics, INC. | $193.19 | 2023-2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $185.89 | 2025 | Gemtesa, Orgovyx |
| Merck Sharp & Dohme LLC | $105.35 | 2019-2021 | |
| Antares Pharma, INC. | $93.17 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $52.40 | 2019-2020 | |
| Endo USA, INC. | $51.38 | 2025 | Xiaflex |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.04 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $39.59 | 2020-2021 | |
| Neotract INC. | $26.29 | 2020 | |
| Corcept Therapeutics | $25.14 | 2023 | Korlym |
| Amarin Pharma, INC. | $25.00 | 2021 | |
| Agiliti Surgical, INC. | $24.23 | 2025 | Koelis Trinity Mri/US Fusion |
| Tolmar Pharmaceuticals, INC. | $23.41 | 2019 | |
| Abbvie INC. | $23.00 | 2021 | |
| Laborie Medical Technologies Corp. | $22.86 | 2025 | |
| Nestle Healthcare Nutrition INC. | $22.73 | 2022 | |
| Myriad Genetic Laboratories, INC. | $22.13 | 2023 | Prolaris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.67 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.00 | 2021 | |
| Verity Pharmaceuticals INC. | $20.00 | 2021 | |
| Collegium Pharmaceutical, INC. | $18.74 | 2019 | |
| Myovant Sciences INC. | $18.53 | 2021 | |
| Ironwood Pharmaceuticals, INC | $17.13 | 2020 | |
| Coloplast Corp | $17.04 | 2023 | Titan |
| Allergan, INC. | $16.26 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.11 | 2023 | Seglentis |
| Clarus Therapeutics INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Wolfson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.